Teimourian Shahram, De Boer Martin, Roos Dirk, Isaian Anna, Moghanloo Ehsan, Lashkary Sharhzad, Hassani Bita, Mollanoori Hasan, Babaei Vahid, Azarnezhad Asaad
Department of Medical Genetics, Iran University of Medical Sciences IUMS, Tehran, Iran; Pediatric Infectious Diseases Research Center, Department of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sanquin Research, and Karl Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Immunol Lett. 2017 Jul;187:7-13. doi: 10.1016/j.imlet.2017.04.012. Epub 2017 Apr 23.
Leukocyte adhesion deficiency type 1 (LAD-I) is a rare, autosomal recessive disorder of neutrophil migration, characterized by severe, recurrent bacterial infections, inadequate pus formation and impaired wound healing. The ITGB2 gene encodes the β2 integrin subunit (CD18) of the leukocyte adhesion cell molecules, and mutations in this gene cause LAD-I. The aim of the current study was to investigate the mutations in patients diagnosed with LAD-I and functional studies of the impact of two previously reported and a novel mutation on the expression of the CD18/CD11a heterodimer.
Blood samples were taken from three patients who had signed the consent form. Genomic DNA was extracted and ITGB2 exons and flanking intronic regions were amplified by polymerase chain reaction. Mutation screening was performed after Sanger sequencing of PCR products. For functional studies, COS-7 cells were co-transfected with an expression vector containing cDNA encoding mutant CD18 proteins and normal CD11a. Flow cytometry analysis of CD18/CD11a expression was assessed by dimer-specific IB4 monoclonal antibody.
Two previously reported mutations and one novel mutation,p. Cys562Tyr, were found. All mutations reduced CD18/CD11 heterodimer expression.
Our strategy recognized the p.Cys562Tyr mutation as a pathogenic alteration that does not support CD18 heterodimer formation. Therefore, it can be put into a panel of carrier and prenatal diagnosis programs.
1型白细胞黏附缺陷症(LAD-I)是一种罕见的常染色体隐性中性粒细胞迁移障碍疾病,其特征为严重的复发性细菌感染、脓液形成不足及伤口愈合受损。ITGB2基因编码白细胞黏附细胞分子的β2整合素亚基(CD18),该基因的突变会导致LAD-I。本研究的目的是调查被诊断为LAD-I的患者的突变情况,并对两个先前报道的突变以及一个新突变对CD18/CD11a异二聚体表达的影响进行功能研究。
采集了三名签署了知情同意书的患者的血样。提取基因组DNA,通过聚合酶链反应扩增ITGB2外显子及其侧翼内含子区域。对PCR产物进行桑格测序后进行突变筛查。对于功能研究,将COS-7细胞与含有编码突变型CD18蛋白和正常CD11a的cDNA的表达载体共转染。通过二聚体特异性IB4单克隆抗体对CD18/CD11a表达进行流式细胞术分析。
发现了两个先前报道的突变和一个新突变p.Cys562Tyr。所有突变均降低了CD18/CD11异二聚体的表达。
我们的策略将p.Cys562Tyr突变识别为一种不支持CD18异二聚体形成的致病改变。因此,它可纳入携带者和产前诊断程序组。